Skip to Navigation

Amitava Chattopadhyay


Amitava Chattopadhyay
Emerging Market Multinationals - Amitava Chattopadhyay


Ranbaxy Laboratories Limited: At the Crossroads

Ranbaxy Laboratories Limited: At the Crossroads

 

 

The case describes the challenges facing Ranbaxy, the third largest pharmaceutical company in India, which has set itself the goal of moving from the branded generic space to the greater value added branded pharmaceutical space. It has developed a one-a-day delivery system for ciprofloxacin a widely used antibiotic that is about to go off patent. Having sold the rights for the drug delivery system for markets outside India and the CIS to Bayer, the inventor of ciprofloxacin, Ranbaxy is wondering how it should market this new formulation in the India market in particular.


Teaching Objectives

The case poses several interesting questions. First, how should the one-a-day formulation of ciprofloxacin, to be called Cifran OD in India, be positioned? Ranbaxy currently markets ciprofloxacin under the name of Cifran as a branded generic in India. Should Cifran be discontinued when Cifran OD is launched? How should the Cifran OD positioning be implemented? Should the OD formulation be marketed by Ranbaxy alone or should it be co-marketed in collaboration with other local and global pharmaceutical players? The latter question facilitates an interesting discussion of when and how should one collaborate with competitors.

The case has been used for both MBA and executive audiences. It can be used in an introductory marketing course to highlight the power of good positioning. It can also be used in a course on pharmaceutical marketing or a course on how companies from emerging markets can climb the value added business ladder.



Download PDF


 

  Nov 1, 2003 | Cases




Download PDF



SHARE


 

Your email address will not be published. Required fields are marked *


Recent Tweets



Sat, 14 Dec @ 01:08 am

Completely moronic request by a moron who has been given power by still another moron who was elrcted by??? "Kennedy’s Lawyer Has Asked the F.D.A. to Revoke Approval of the Polio Vaccine"

Thu, 21 Nov @ 01:13 am

Uh Oh! Will #PMMODI throw #GAUTAMADANI under the bus? US too important to mess with. "Gautam Adani charged in US over alleged $250mn bribery scheme" via @FT

Fri, 18 Oct @ 03:39 am

Hello #Modi, what now? Not so easy when US gets into the game! "U.S. Charges Indian Official in New York Assassination Plot"

Sun, 22 Sep @ 04:05 pm

Brought down a peg or two, ey, #ElonMusk? "Elon Musk complies with Brazilian court’s legal demands for X" via @FT

Wed, 18 Sep @ 02:39 am

Two of a kind. Sadly, no surprise. "Live news: Donald Trump says he will meet India’s Narendra Modi next week" via @FT

Sat, 14 Sep @ 08:14 pm

#SkyTeamLounge at Vancouver. The sheer incompetence of screening this morning left me flabbergasted! 10 minutes of fiddling with each passenger's boarding card to check them in. Seriously, this is 2024! Should be smooth and automated. Given long queue, we never made it!


  Close AboutPapersCasesBooksTeachingMusingsMediaGalleryAsk Amitava